InflaRx Gears Up for a Prominent January Presence
InflaRx N.V. (Nasdaq: IFRX), a pioneering biopharmaceutical company specializing in anti-inflammatory treatments, has announced its active participation in key events scheduled for the week of January 13, 2025. These events coincide with the renowned J.P. Morgan Healthcare Conference, marking an important time for industry leaders to converge and exchange insights.
Details of InflaRx's Involvement in Key Events
Among the anticipated gatherings, InflaRx will be featured at the LifeSci Partners Corporate Access Event, where one-on-one meetings will facilitate direct discussions about the company's innovative efforts. This event is set for January 14 and 15, providing a platform for meaningful interactions with investors and partners.
Additionally, InflaRx will hold a workshop at the Biotech Showcase 2025 on January 15, covering vital topics related to the urgent need for new solutions against various disease threats—a discussion enriched by input from government and NGO representatives.
About InflaRx and Its Innovative Approach
InflaRx stands out in its field with innovative anti-C5a and anti-C5aR technologies. By focusing on the complement system, InflaRx aims to develop potent inhibitors targeting the C5a inflammatory factor and its receptor, C5aR. This unique approach is crucial in addressing a range of inflammatory diseases.
At the forefront of InflaRx's product offerings is vilobelimab, an intravenous anti-C5a monoclonal antibody that has shown significant clinical activity across various studies. Designed to bind specifically to free C5a, vilobelimab is a first-in-class therapy that promises to modify disease trajectories effectively.
Additionally, the company is advancing INF904, a small molecule inhibitor of the C5a receptor that will offer a novel oral treatment option. This diversifies the company's product pipeline and enhances treatment accessibility for patients.
Corporate Structure and Global Reach
Founded in 2007, InflaRx has established a strong presence with offices and subsidiaries located in Jena, Munich, and Ann Arbor, MI. This expansive footprint enables the company to maintain its commitment to innovation and patient care from a global perspective.
Connect with InflaRx
For individuals wishing to learn more about their initiatives, InflaRx encourages visits to their official website, where they provide comprehensive information about their research and developments.
Frequently Asked Questions
What major events will InflaRx participate in January 2025?
InflaRx will participate in the LifeSci Partners Corporate Access Event and the Biotech Showcase 2025.
What is the focus of InflaRx’s treatments?
The company specializes in anti-inflammatory therapeutics, specifically targeting the complement system with innovations like vilobelimab.
Where are InflaRx's offices located?
InflaRx has offices in Jena and Munich, Germany, and in Ann Arbor, MI, USA.
What is vilobelimab?
Vilobelimab is InflaRx's lead product candidate, a first-in-class anti-C5a monoclonal antibody delivered intravenously.
How can I contact InflaRx for more information?
For further inquiries, individuals can reach out via email, or visit their website for additional resources.
